Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Channel Fluorescence Digital Pathology Scanning

July 24, 2012

WETZLAR, Germany, July 24, 2012 /PRNewswire/ — Leica Microsystems announces the release of the SCN400 2.2 scanning platform. Batch processing in both brightfield and multi-channel fluorescence, coupled with user-friendly workflows, makes the SCN400 2.2 an all-round high performance solution for digital pathology scanning.

With up to 5 fluorescence channels per slide, the SCN400 2.2 provides a truly flexible whole slide scanning solution. The ability to capture multiple markers on a single sample, with clear focus and channel separation, ensures that researchers maximize results from precious or rare samples. Capacity for multiple filter cubes enables up to 7 distinct fluorescence channels to be utilized across a scanning batch, providing flexibility for the varied samples in research and pharmaceutical laboratories.

The SCN400 2.2 is optimized to meet the requirements of both brightfield and fluorescence imaging in a single scanning platform. Monochrome detectors for fluorescence provide excellent separation of individual fluorophores that may be close in wavelength, while color detectors for brightfield provide excellent digital slide capture quality.

For brightfield imaging the advanced tissue finding system automatically identifies areas for capture, while Leica’s patented Dynamic Focus removes the overhead of slide pre-mapping, rapidly scanning high quality whole slide images. With the addition of the SL801 autoloader with capacity for 384 slides, the SCN400 2.2 becomes a truly automated high-throughput system.

Dr. Donal O’Shea, Head of Digital Pathology at Leica Microsystems, says “Providing a streamlined workflow for tissue-based research that facilitates quantitative analysis and flexible solutions for multi-user laboratories is a continued focus for Leica. The advanced brightfield and fluorescence imaging capacity in this release provides an optimal single-platform scanner for the varied samples used by biomarker discovery and translational researchers.”

Total Digital Pathology from Leica provides complete end-to-end solutions for scanning, management and analysis of digital pathology images. As part of this portfolio, the SCN400 2.2 provides unparalleled flexibility and performance, to make slide scanning a simple, integrated step in the pathology workflow.
To learn more about the SCN400 2.2, please visit:
http://www.leica-microsystems.com/products/digital-pathology/scan/details/product/leica-scn400-2/
http://www.leica-microsystems.com/products/digital-pathology/scan/details/product/leica-scn400-f/

Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise.

Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in three divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division and Medical Division.

The company is represented in over 100 countries with 6 manufacturing facilities in 5 countries, sales and service organizations in 20 countries, and an international network of dealers. The company is headquartered in Wetzlar, Germany.

SOURCE Leica Microsystems


Source: PR Newswire